Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I

Natalia Gomez-Ospina, Samantha G. Scharenberg, Nathalie Mostrel, Rasmus O. Bak, Sruthi Mantri, Rolen M. Quadros, Channabasavaiah B Gurumurthy, Ciaran Lee, Gang Bao, Carlos J. Suarez, Shaukat Khan, Kazuki Sawamoto, Shunji Tomatsu, Nitin Raj, Laura D. Attardi, Laure Aurelian, Matthew H. Porteus

Research output: Contribution to journalArticle

Abstract

Lysosomal enzyme deficiencies comprise a large group of genetic disorders that generally lack effective treatments. A potential treatment approach is to engineer the patient’s own hematopoietic system to express high levels of the deficient enzyme, thereby correcting the biochemical defect and halting disease progression. Here, we present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targets the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels, maintain long-term repopulation and multi-lineage differentiation potential, and can improve biochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis type I. These studies provide support for the development of genome-edited CD34+ hematopoietic stem and progenitor cells as a potential treatment for Mucopolysaccharidosis type I. The safe harbor approach constitutes a flexible platform for the expression of lysosomal enzymes making it applicable to other lysosomal storage disorders.

Original languageEnglish (US)
Article number4045
JournalNature communications
Volume10
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

Mucopolysaccharidosis I
stem cells
genome
Human Genome
Hematopoietic Stem Cells
Stem cells
enzymes
Genes
Enzymes
harbors
Ports and harbors
hematopoietic system
Iduronidase
Clustered Regularly Interspaced Short Palindromic Repeats
cells
disorders
Hematopoietic System
editing
Inborn Genetic Diseases
abnormalities

ASJC Scopus subject areas

  • Chemistry(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Physics and Astronomy(all)

Cite this

Gomez-Ospina, N., Scharenberg, S. G., Mostrel, N., Bak, R. O., Mantri, S., Quadros, R. M., ... Porteus, M. H. (2019). Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nature communications, 10(1), [4045]. https://doi.org/10.1038/s41467-019-11962-8

Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. / Gomez-Ospina, Natalia; Scharenberg, Samantha G.; Mostrel, Nathalie; Bak, Rasmus O.; Mantri, Sruthi; Quadros, Rolen M.; Gurumurthy, Channabasavaiah B; Lee, Ciaran; Bao, Gang; Suarez, Carlos J.; Khan, Shaukat; Sawamoto, Kazuki; Tomatsu, Shunji; Raj, Nitin; Attardi, Laura D.; Aurelian, Laure; Porteus, Matthew H.

In: Nature communications, Vol. 10, No. 1, 4045, 01.12.2019.

Research output: Contribution to journalArticle

Gomez-Ospina, N, Scharenberg, SG, Mostrel, N, Bak, RO, Mantri, S, Quadros, RM, Gurumurthy, CB, Lee, C, Bao, G, Suarez, CJ, Khan, S, Sawamoto, K, Tomatsu, S, Raj, N, Attardi, LD, Aurelian, L & Porteus, MH 2019, 'Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I', Nature communications, vol. 10, no. 1, 4045. https://doi.org/10.1038/s41467-019-11962-8
Gomez-Ospina N, Scharenberg SG, Mostrel N, Bak RO, Mantri S, Quadros RM et al. Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. Nature communications. 2019 Dec 1;10(1). 4045. https://doi.org/10.1038/s41467-019-11962-8
Gomez-Ospina, Natalia ; Scharenberg, Samantha G. ; Mostrel, Nathalie ; Bak, Rasmus O. ; Mantri, Sruthi ; Quadros, Rolen M. ; Gurumurthy, Channabasavaiah B ; Lee, Ciaran ; Bao, Gang ; Suarez, Carlos J. ; Khan, Shaukat ; Sawamoto, Kazuki ; Tomatsu, Shunji ; Raj, Nitin ; Attardi, Laura D. ; Aurelian, Laure ; Porteus, Matthew H. / Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I. In: Nature communications. 2019 ; Vol. 10, No. 1.
@article{6ef187ed1f5c4cde8458a00caabaade6,
title = "Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I",
abstract = "Lysosomal enzyme deficiencies comprise a large group of genetic disorders that generally lack effective treatments. A potential treatment approach is to engineer the patient’s own hematopoietic system to express high levels of the deficient enzyme, thereby correcting the biochemical defect and halting disease progression. Here, we present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targets the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels, maintain long-term repopulation and multi-lineage differentiation potential, and can improve biochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis type I. These studies provide support for the development of genome-edited CD34+ hematopoietic stem and progenitor cells as a potential treatment for Mucopolysaccharidosis type I. The safe harbor approach constitutes a flexible platform for the expression of lysosomal enzymes making it applicable to other lysosomal storage disorders.",
author = "Natalia Gomez-Ospina and Scharenberg, {Samantha G.} and Nathalie Mostrel and Bak, {Rasmus O.} and Sruthi Mantri and Quadros, {Rolen M.} and Gurumurthy, {Channabasavaiah B} and Ciaran Lee and Gang Bao and Suarez, {Carlos J.} and Shaukat Khan and Kazuki Sawamoto and Shunji Tomatsu and Nitin Raj and Attardi, {Laura D.} and Laure Aurelian and Porteus, {Matthew H.}",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41467-019-11962-8",
language = "English (US)",
volume = "10",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Human genome-edited hematopoietic stem cells phenotypically correct Mucopolysaccharidosis type I

AU - Gomez-Ospina, Natalia

AU - Scharenberg, Samantha G.

AU - Mostrel, Nathalie

AU - Bak, Rasmus O.

AU - Mantri, Sruthi

AU - Quadros, Rolen M.

AU - Gurumurthy, Channabasavaiah B

AU - Lee, Ciaran

AU - Bao, Gang

AU - Suarez, Carlos J.

AU - Khan, Shaukat

AU - Sawamoto, Kazuki

AU - Tomatsu, Shunji

AU - Raj, Nitin

AU - Attardi, Laura D.

AU - Aurelian, Laure

AU - Porteus, Matthew H.

PY - 2019/12/1

Y1 - 2019/12/1

N2 - Lysosomal enzyme deficiencies comprise a large group of genetic disorders that generally lack effective treatments. A potential treatment approach is to engineer the patient’s own hematopoietic system to express high levels of the deficient enzyme, thereby correcting the biochemical defect and halting disease progression. Here, we present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targets the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels, maintain long-term repopulation and multi-lineage differentiation potential, and can improve biochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis type I. These studies provide support for the development of genome-edited CD34+ hematopoietic stem and progenitor cells as a potential treatment for Mucopolysaccharidosis type I. The safe harbor approach constitutes a flexible platform for the expression of lysosomal enzymes making it applicable to other lysosomal storage disorders.

AB - Lysosomal enzyme deficiencies comprise a large group of genetic disorders that generally lack effective treatments. A potential treatment approach is to engineer the patient’s own hematopoietic system to express high levels of the deficient enzyme, thereby correcting the biochemical defect and halting disease progression. Here, we present an efficient ex vivo genome editing approach using CRISPR-Cas9 that targets the lysosomal enzyme iduronidase to the CCR5 safe harbor locus in human CD34+ hematopoietic stem and progenitor cells. The modified cells secrete supra-endogenous enzyme levels, maintain long-term repopulation and multi-lineage differentiation potential, and can improve biochemical and phenotypic abnormalities in an immunocompromised mouse model of Mucopolysaccharidosis type I. These studies provide support for the development of genome-edited CD34+ hematopoietic stem and progenitor cells as a potential treatment for Mucopolysaccharidosis type I. The safe harbor approach constitutes a flexible platform for the expression of lysosomal enzymes making it applicable to other lysosomal storage disorders.

UR - http://www.scopus.com/inward/record.url?scp=85071896825&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071896825&partnerID=8YFLogxK

U2 - 10.1038/s41467-019-11962-8

DO - 10.1038/s41467-019-11962-8

M3 - Article

VL - 10

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

IS - 1

M1 - 4045

ER -